Correspondence  |   September 2003
Amiodarone for Conversion of Atrial Fibrillation
Author Notes
  • Santa Rosa, California.
Article Information
Correspondence   |   September 2003
Amiodarone for Conversion of Atrial Fibrillation
Anesthesiology 9 2003, Vol.99, 756. doi:
Anesthesiology 9 2003, Vol.99, 756. doi:
To the Editor:—
I would like to thank Dr. Amar for his comprehensive and informative review of atrial tachyarrhythmias. 1 It was stated that amiodarone was not superior to placebo for conversion of recent onset atrial fibrillation (AF) unrelated to surgery. It is true that a few studies did not find a significant difference in conversion rates compared to placebo. 2 However, others have shown a significant increase in conversion rates with respect to placebo, and studies comparing amiodarone to Vaughn Williams class 1c drugs have shown comparable rates of conversion. 3–7 Reviews of the management of AF and of amiodarone use have concluded that it is effective for pharmacologic conversion of recent onset AF. 8,9 It has been recommended as a second-line agent after β-blockers in the conversion of adrenergically mediated AF, which may represent a substantial proportion of postoperative AF without other underlying pathology. Although it may not be a first-line agent for the conversion of AF, amiodarone is increasingly used because of its low cardiotoxicity and is used by many electrophysiologists for AF conversion.
Amar D: Perioperative arial tachyarrhythmias. A nesthesiology 2002; 97: 1618–23Amar, D
Zehender M, Hohnloser S, Muller B, Meinertz T, Just H: Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: Results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992; 19: 1054–9Zehender, M Hohnloser, S Muller, B Meinertz, T Just, H
Noe M, Stajer D, Horvat M: Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol 1995; 75: 693–7Noe, M Stajer, D Horvat, M
Cowan JC, Gardiner P, Reid DS, Newell DJ, Campbell RWF: Comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected acute myocardial infarction. J Cardiovasc Pharmacol 1986; 8: 252–6Cowan, JC Gardiner, P Reid, DS Newell, DJ Campbell, RWF
Donovan KD, Power BM, Hockings BEF, Dobb GJ, Lee K-Y: Intravenous flecainide versus amiodarone of recent-onset atrial fibrillation. Am J Cardiol 1995; 75: 693–7Donovan, KD Power, BM Hockings, BEF Dobb, GJ Lee, K-Y
Di Biasi P, Scrofani R, Paje A, Cappiello E, Mangini A, Santoli C: Intravenous amiodarone versus propafenone for atrial fibrillation and flutter after cardiac operation. Eur J Cardiothorac Surg 195; 9: 587–91Di Biasi, P Scrofani, R Paje, A Cappiello, E Mangini, A Santoli, C
Larbuisson R, Venneman I, Stiels B: The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery. J Cardiothorac Vas Anesth 1996; 10: 229–34Larbuisson, R Venneman, I Stiels, B
ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary. Circulation 2001; 104: 2118–50NA,
Connolly SJ: Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999; 100: 2025–34Connolly, SJ